MA49908A - Composés inhibant la protéine mcl-1 - Google Patents

Composés inhibant la protéine mcl-1

Info

Publication number
MA49908A
MA49908A MA049908A MA49908A MA49908A MA 49908 A MA49908 A MA 49908A MA 049908 A MA049908 A MA 049908A MA 49908 A MA49908 A MA 49908A MA 49908 A MA49908 A MA 49908A
Authority
MA
Morocco
Prior art keywords
mcl
protein inhibitors
inhibitors
protein
Prior art date
Application number
MA049908A
Other languages
English (en)
Inventor
Sean P Brown
Brian Alan Lanman
Kexue Li
Yunxiao Li
Anthony B Reed
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA49908A publication Critical patent/MA49908A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA049908A 2017-08-18 2018-08-17 Composés inhibant la protéine mcl-1 MA49908A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762547589P 2017-08-18 2017-08-18

Publications (1)

Publication Number Publication Date
MA49908A true MA49908A (fr) 2021-04-28

Family

ID=63579748

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049908A MA49908A (fr) 2017-08-18 2018-08-17 Composés inhibant la protéine mcl-1

Country Status (5)

Country Link
US (1) US11364248B2 (fr)
EP (1) EP3668878B1 (fr)
ES (1) ES3036998T3 (fr)
MA (1) MA49908A (fr)
WO (1) WO2019036575A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6453507B2 (ja) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Mcl−1タンパク質を阻害する化合物
MA50033A (fr) 2017-08-29 2020-07-08 Amgen Inc Composés macrocycliques permettant d'inhiber la protéine mcl-1
EP3762393B1 (fr) 2018-03-05 2023-01-11 Amgen Inc. Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1
JP6899975B2 (ja) 2018-05-14 2021-07-07 ギリアード サイエンシーズ, インコーポレイテッド Mcl−1阻害剤
WO2020147802A1 (fr) * 2019-01-18 2020-07-23 Ascentage Pharma (Suzhou) Co., Ltd. Spiroéthers macrocycliques utilisés en tant qu'inhibiteurs de mcl-1
KR20220034136A (ko) 2019-07-09 2022-03-17 얀센 파마슈티카 엔.브이. Mcl-1 억제제로서의 거대환식 스피로사이클 유도체
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
CA3294692A1 (en) 2019-11-26 2026-03-02 Gilead Sciences, Inc. Processes and intermediates for preparing mcl1 inhibitors
KR20230023008A (ko) * 2020-06-10 2023-02-16 얀센 파마슈티카 엔.브이. Mcl-1의 억제제로서의 마크로사이클릭 2-아미노-3-플루오로-부트-3-엔아미드
US12202782B2 (en) 2020-11-19 2025-01-21 Gilead Sciences, Inc. Processes and intermediates for preparing MCL1 inhibitors
EP4263558B1 (fr) 2020-12-17 2025-02-12 JANSSEN Pharmaceutica NV Composés spirocycliques macrocycliques en tant qu'inhibiteurs de mcl-1
US20240239812A1 (en) 2021-04-26 2024-07-18 Janssen Pharmaceutica Nv Macrocyclic 2-allyltetrahydrofurans as inhibitors of mcl-1
TWI861509B (zh) 2021-06-11 2024-11-11 美商基利科學股份有限公司 Mcl-1抑制劑與抗體藥物接合物之組合
JP7900421B2 (ja) 2021-06-11 2026-08-04 ギリアード サイエンシーズ, インコーポレイテッド Mcl-1阻害剤と抗がん剤との組み合わせ
KR20240107105A (ko) 2021-11-16 2024-07-08 얀센 파마슈티카 엔브이 Mcl-1의 억제제로서의 매크로사이클릭 2-아미노-부트-3-엔아미드

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US6472375B1 (en) 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
KR101511074B1 (ko) 2007-04-16 2015-04-13 애브비 인코포레이티드 7-치환된 인돌 Mcl-1 억제제
US20130035304A1 (en) 2010-01-29 2013-02-07 Walensky Loren D Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
WO2013052943A2 (fr) 2011-10-06 2013-04-11 The Regents Of The University Of Michgian Inhibiteurs à petite molécule de mcl-1 et leurs utilisations
EP2831067B1 (fr) 2012-03-29 2017-11-01 The Regents Of The University Of Michigan Inhibiteurs de mcl-1 à petite molécule et utilisations de ceux-ci
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
US11306107B2 (en) * 2016-02-25 2022-04-19 Amgen Inc. Compounds that inhibit MCL-1 protein
JP6453507B2 (ja) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Mcl−1タンパク質を阻害する化合物
MA50033A (fr) 2017-08-29 2020-07-08 Amgen Inc Composés macrocycliques permettant d'inhiber la protéine mcl-1
EP3762393B1 (fr) 2018-03-05 2023-01-11 Amgen Inc. Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1

Also Published As

Publication number Publication date
WO2019036575A1 (fr) 2019-02-21
EP3668878B1 (fr) 2025-05-21
ES3036998T3 (en) 2025-09-26
EP3668878A1 (fr) 2020-06-24
US11364248B2 (en) 2022-06-21
US20200360399A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
EP4029868B1 (fr) Inhibiteurs de mcl-1
EP3801265B1 (fr) Débitmètre urinaire
IL283639A (en) Kif18a inhibitors
IL269196A (en) Novel inhibitors
FI3601297T3 (fi) Mcl-1-proteiinia estäviä yhdisteitä
EP3555124C0 (fr) Tcr nyeso
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
DK3571192T3 (da) Jak1-selektive inhibitorer
EP3781060A4 (fr) Cryosonde
DK3737403T3 (da) Modificerede adenovira
DK3630744T3 (da) Pyrazol-magl-inhibitorer
EP3784463A4 (fr) Fluorosulfones
EP3810860C0 (fr) Coupleur
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
EP3792200A4 (fr) Conteneur-citerne
EP3797632A4 (fr) Chaussure
EP3745904C0 (fr) Poignée de bâton
EP3600301A4 (fr) Inhibiteurs de kdm4
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
EP3721129C0 (fr) Cryosphère
CL2018000262S1 (es) Zapato
EP3801525A4 (fr) Inhibiteurs de la prolyl-arnt-synthétase
EP3844177A4 (fr) Polythérapies
DK3587968T3 (da) Fluidsystem
DK3752258T3 (da) Trampolin